Laddar...
Effect of a Dual PPAR α/γ agonist on Insulin Sensitivity in Patients of Type 2 Diabetes with Hypertriglyceridemia- Randomized double-blind placebo-controlled trial
Saroglitazar is a dual PPAR-α/γ agonist approved for the treatment of diabetic dyslipidemia. In addition to reduction in atherogenic lipids, it may also contribute to improvement in insulin sensitivity through PPAR-α/γ agonism, which remains unexplored. We conducted a randomized, double-blind, place...
Sparad:
| I publikationen: | Sci Rep |
|---|---|
| Huvudupphovsmän: | , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Nature Publishing Group UK
2019
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6908698/ https://ncbi.nlm.nih.gov/pubmed/31831868 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-55466-3 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|